Neuroendocrine tumors (NETs) are relatively uncommon. They typically arise in the
gastrointestinal tract and lungs, and their incidence seems to be rising. Most patients have advanced
disease at the time of diagnosis and many more will relapse after surgery. There is thus a great need
for improvements in therapy for advanced neuroendocrine tumors. This article reviews the current
therapy for both pancreatic NETs and non-pancreatic gastrointestinal NETs, and discusses recent
advances in NET management with an emphasis on targeted therapy.
Keywords: Carcinoid tumors, neuroendocrine tumors, targeted therapy, therapy.
Rights & PermissionsPrintExport